Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study.

Abstract

In developed countries, prostate cancer is the third most common cause of death from cancer in men. Unfortunately, whilst accumulating clinical data have suggested that taxanes may prolong the survival in a subset of men with prostate carcinoma, the dose and duration of administration of these drugs are limited by their significant systemic toxicities due… (More)
DOI: 10.1016/j.ejca.2010.08.018

Topics

9 Figures and Tables

Cite this paper

@article{Elsadek2010DevelopmentOA, title={Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study.}, author={Bakheet E M Elsadek and Ralph Graeser and Norbert Esser and Cynthia Sch{\"a}fer-Obodozie and Khalid Abu Ajaj and Clemens Unger and Andr{\'e} Warnecke and Tahia H. Saleem and Nagla T El-Melegy and Hafez Madkor and Felix Kratz}, journal={European journal of cancer}, year={2010}, volume={46 18}, pages={3434-44} }